TD Cowen Begins Coverage on Inventiva (NASDAQ:IVA)

Equities researchers at TD Cowen initiated coverage on shares of Inventiva (NASDAQ:IVA) in a research note issued on Friday, Marketbeat Ratings reports. The firm set a “buy” rating and a $10.00 price target on the stock. TD Cowen’s price target would indicate a potential upside of 252.11% from the stock’s previous close.

Several other equities research analysts also recently commented on the stock. Stifel Nicolaus decreased their target price on shares of Inventiva from $20.00 to $17.00 and set a “buy” rating for the company in a research report on Friday, November 22nd. HC Wainwright reissued a “buy” rating and set a $13.00 target price on shares of Inventiva in a research report on Thursday, January 30th. Finally, UBS Group assumed coverage on shares of Inventiva in a research report on Tuesday, November 12th. They set a “neutral” rating and a $3.00 target price for the company. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $12.60.

Inventiva Trading Up 3.6 %

Shares of NASDAQ IVA opened at $2.84 on Friday. The firm’s 50-day moving average price is $2.33 and its 200-day moving average price is $2.36. Inventiva has a 1-year low of $1.53 and a 1-year high of $4.50.

About Inventiva

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.